The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) in combination with chemo-therapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express programmed death ligand-1 (PD-L1; combined positive score [CPS] ≥10), as determined by an FDA-approved test. Read More…
Among cancer survivors with chronic musculoskeletal pain, auricular acupuncture—also called battlefield acupuncture—was inferior to electroacupuncture at reducing pain and was associated with higher rates of discontinuation, according to a new study. Read More…
The ongoing fallout of the COVID-19 pandemic has been fierce, and cancer patients have been affected in myriad ways. From a higher risk for SARS-CoV-2 infection and severe COVID-19 disease to a population-level reduction in screening and surveillance, outcomes for cancer patients have worsened during the pandemic. Read More…
Overall survival (OS) is improved when patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC) or esophagogastric junction adenocarcinoma (EGJ) receive the checkpoint inhibitor pembrolizumab with chemotherapy rather than chemotherapy alone, according to data from the phase 3 KEYNOTE-590 trial. Read More…
The FDA approved osimertinib (Tagrisso, AstraZeneca) for adjuvant therapy after tumor resection in adults with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. Read More…